E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Macula edema resulting from central retinal vein occlusion in the eye |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This investigator driven study is designed to evaluate the safety and efficacy of intravitreal ranibizumab for the treatment of macular edema following central retinal vein occlusion (CRVO). |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients who at baseline • have a BCVA letter score in the study eye between finger count5 (1m distance) and 65 (4m distance) (approximately 20/3205/400 5/200 to 20/40 Snellen equivalent and 1,846 – 0,34 logMar) using an ETDRS chart measured at 4 meters or at 1 m. • have cystoid macular edema secondary to CRVO (ischemic or non ischemic - defined by fluorescein angiography) of ≥300µm.. In case of development of neovascularistation laser photocoagulation will be performed as recommended by the “Central Retinal Vein Occlusion Study • maximum history of symptoms: 6 months8 weeks • will be willing to return for all scheduled visits
|
|
E.4 | Principal exclusion criteria |
• A condition that in the opinion of the investigator would preclude a patient’s participation in the study, e.g., unstable medical status including blood pressure. Patients with hypertension for whom a change in antihypertensive treatment was initiated within 2 months preceding Day 1 should not be enrolled unless blood pressure is maintained for at least 1 month below 150/95 mm Hg by antihypertensive treatment. • History of systemic (e.g., oral, intravenously, intramuscular, epidural, bursal) corticosteroids within 2 months prior to randomization or topical, rectal, or inhaled corticosteroids in current use more than 2 times per week. • significant ischaemic heart disease (history of myocardial infarction less than 6 months ago, unstable angina, ischaemic ECG) • history of heart disease (NYHA grade III-VI) • history of cerebrovascular event less than 6 months ago • grossly abnormal urea and electrolytes • history of significant pulmonary disease • haematocrit (PCV) below 0,37
Concurrent Ocular Conditions • Vitreomacular traction or epiretinal membrane in the study eye evident by slit lamp examination or by OCT • Active intraocular inflammation (grade trace or above) in either eye • Any active infection involving ocular adnexa including infectious conjunctivitis, keratitis, scleritis, endophthalmitis, as well as idiopathic or autoimmune-associated uveitis in either eye • Structural damage to the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), or organized hard exudate plaques • Ocular disorders in the study eye that may confound interpretation of study results, including retinal detachment, macular hole, or choroidal neovascularization of any cause (e.g., AMD, ocular histoplasmosis, or pathologic myopia) • Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the 28-week12-month study period • History of uncontrolled glaucoma (defined as intraocular pressure ≥25 mm Hg despite treatment with anti-glaucoma medication) or low tension glaucoma in the study eye • History of glaucoma filtration surgery, corneal transplant surgery in the study eye • Ocular conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids. Chronic concomitant therapy is defined as multiple doses taken daily for three or more consecutive days at any time within 6 months prior to screening or during the course of the study
Systemic Conditions • Blood pressure: Systolic ≥ 150 mmHg and/or Diastolic ≥ 95 mmHg o If blood pressure is brought and maintained for at least 1 month below 150/95 mm Hg by antihypertensive treatment, patient can become eligible • History of chronic renal failure requiring dialysis or kidney transplant • Pre-menopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization; use of oral contraceptives; barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel; an IUD; or contraceptive hormone implant or patch • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/ml) • Current treatment for active systemic infection • Current use of or likely need for systemic medications known to be toxic to the lens, retina or optic nerve, including Deferoxamine, Chloroquine/ hydroxychloroquine (Plaquenil), Tamoxifen, Phenothiazines and Ethambutol is excluded • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications • Use of anticoagulants during the study, e.g., coumadin, warfarin or heparin. The use of aspirin or clopidogrel is not an exclusion criterion. Other • History of allergy to fluorescein • Inability to obtain fundus photographs, fluorescein angiograms or OCT images of sufficient quality to be analyzed and graded. • History of allergy to humanized antibodies or any component of the ranibizumab formulation • History of hypersensitivity to ranibizumab or to drugs with similar chemical structures • History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin • Inability to comply with study or follow-up procedures
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective is to explore the effect of ranibizumab (RFB002) on visual acuity in patients with macular edema following central retinal vein occlusion in addition to standard treatment with hemodilution. The endpoint will be the visual acuity after 8 weeks |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 3 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |